Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.
A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.
@openFDA and its related website launched February 27.
Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?
The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.
The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.
Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.
The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.
The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.
A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.